salidroside

Overview

Salidroside (p-hydroxyphenethyl β-D-glucopyranoside) is a phenolic glycoside naturally occurring in Rhodiola rosea and related alpine plant species. It consists of a tyrosol aglycone linked to a glucose moiety via a β-glycosidic bond, and is widely regarded as one of the primary bioactive constituents responsible for the adaptogenic and medicinal properties attributed to Rhodiola extracts. Salidroside exhibits a broad spectrum of biological activities, including neuroprotective, anti-inflammatory, antioxidant, cardioprotective, and anticancer effects, which have driven its extensive investigation in both biomedicine and cosmetics.

Mechanistically, salidroside engages multiple intracellular signaling cascades. Its anti-inflammatory activity is partly attributed to suppression of inflammasome-mediated pathways — notably interactions with NLRP3, Caspase-1 (CASP1), and Gasdermin D — as well as modulation of the TLR4/P2X7-NLRP3 signaling pathway. In neurological contexts, salidroside exerts cytoprotective effects on neurons, including retinal ganglion cells, through mechanisms that limit oxidative stress and apoptosis. Its pharmaceutical potential, however, has historically been constrained by the limited natural abundance of Rhodiola species and the toxicity of its biosynthetic precursor tyrosol, motivating a growing body of research into microbial and enzymatic synthesis strategies.

Focus of Latest Publications

Recent publications highlight salidroside as a subject of active investigation across three converging areas: neuroprotection, inflammation biology, and biotechnological production.

Neuroprotection and Ocular Disease A 2026 study in the European Journal of Pharmaceutical Sciences (PMID: 41999785) demonstrated that engineered small extracellular vesicles (sEVs) could serve as targeted delivery vehicles for low-dose salidroside to attenuate retinal ganglion cell degeneration. The study capitalized on the well-documented neuroprotective effects of salidroside, addressing a key pharmacokinetic limitation — its poor ocular bioavailability when administered conventionally. By encapsulating salidroside within engineered sEVs and deploying a mouse model of optic nerve crush, researchers were able to assess whether vesicle-mediated delivery could preserve retinal ganglion cell populations more effectively than free compound alone.

Anti-inflammatory and Rheumatological Activity A 2026 study published in the FASEB Journal (PMID: 42033182) examined the "Tianyu" traditional herbal formulation in the context of rheumatoid arthritis and collagen-induced arthritis models. Molecular docking analyses revealed that salidroside, alongside apigenin, isorhamnetin, kaempferol, and quercetin, bound well to NLRP3, CASP1, and Gasdermin D, with binding energies below −5 kcal/mol. These results implicate salidroside as a potential inhibitor of the NLRP3/Caspase-1/GSDMD-mediated pyroptosis axis — a pathway in which Interleukin 1 beta and IL18 are cleaved and released as pro-inflammatory cytokines driving synovial inflammation. This mechanistic framing positions salidroside as a pyroptosis-modulating agent relevant to chronic inflammatory diseases.

Biosynthesis: Microbial Engineering Two parallel studies in ACS Synthetic Biology (PMIDs: 41979105 and 42048483) addressed the scalable production of salidroside using engineered microorganisms. The first (PMID: 41979105) employed adaptive laboratory evolution in Escherichia coli to overcome tyrosol toxicity — the key bottleneck in salidroside biosynthesis — enabling high-titer production from L-tyrosine. The second (PMID: 42048483) engineered Bacillus subtilis to produce salidroside from potato starch as a low-cost carbon source, incorporating a quorum-sensing-based dynamic regulation system to balance cell growth and biosynthetic flux. Both studies highlight the pharmaceutical value of salidroside and the need for economically viable fermentation routes to replace plant extraction.

Enzymatic Synthesis and Regioselectivity A 2026 study in Bioorganic Chemistry (PMID: 41747362) addressed regioselectivity challenges in UDP-glycosyltransferase-catalyzed reactions, noting that the synthesis of icariside D2 can yield salidroside as an undesired byproduct. Tunnel-block engineering of the glycosyltransferase active site was investigated as a strategy to improve product specificity and eliminate this off-pathway product, underscoring salidroside's structural similarity to glycosylation products of broader pharmacological interest.

Key Publications

Jun Regioselectivity enhancement of UDP-glycosyltransferase via tunnel-block engineering for the exclusive synthesis of icariside D2. (Bioorganic chemistry, 2026, PMID 41747362): "...which results in mixtures of icariside D2 and salidroside."
Jun Engineered small extracellular vesicles provide low-dose salidroside delivery to attenuate retinal ganglion cell degeneration. (European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2026, PMID 41999785): "Several studies have demonstrated the neuroprotective effects of salidroside (Sal)."
May Metabolic Engineering of Bacillus subtilis for High-Level Production of Salidroside from Potato Starch. (ACS synthetic biology, 2026, PMID 42048483): "Salidroside exhibits a diverse range of biological activities and is extensively utilized in the fields of biomedicine and cosmetics."
May Adaptive Laboratory Evolution for Enhanced Tyrosol Tolerance Enables High-Titer Salidroside Production in Escherichia coli. (ACS synthetic biology, 2026, PMID 41979105): "Salidroside, a valuable phenolic glycoside from Rhodiola rosea, holds significant pharmaceutical potential, yet its microbial synthesis is inhibited by the toxicity of the precursor tyrosol."
May The "Tianyu" Formulation Alleviates Rheumatoid Arthritis by Modulating the NLRP3/Caspase-1/GSDMD-Mediated Pyroptosis Pathway. (FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026, PMID 42033182): "...molecular docking showed that all five major compounds (Apigenin, Isorhamnetin, Kaempferol, Quercetin, and Salidroside) bound well to NLRP3, Caspase-1, and GSDMD, with all binding energies below -5 kcal/mol."